Table of Contents Author Guidelines Submit a Manuscript
Advances in Pharmacological Sciences
Volume 2016, Article ID 3094783, 12 pages
http://dx.doi.org/10.1155/2016/3094783
Research Article

Changes in IL-2 and IL-10 during Chronic Administration of Isoniazid, Nevirapine, and Paracetamol in Rats

Department of Pharmacology, University of the Free State, P.O. Box 339, Bloemfontein 9300, South Africa

Received 24 August 2016; Revised 10 October 2016; Accepted 23 October 2016

Academic Editor: Paola Patrignani

Copyright © 2016 Zanelle Bekker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. P. Holt and C. Ju, “Mechanisms of drug-induced liver injury,” AAPS Journal, vol. 8, no. 1, pp. E48–E54, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Jaeschke, G. J. Gores, A. I. Cederbaum, J. A. Hinson, D. Pessayre, and J. J. Lemasters, “Mechanisms of hepatotoxicity,” Toxicological Sciences, vol. 65, no. 2, pp. 166–176, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. D. H. Adams, C. Ju, S. K. Ramaiah, J. Uetrecht, and H. Jaeschke, “Mechanisms of immune-mediated liver injury,” Toxicological Sciences, vol. 115, no. 2, pp. 307–321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. W. R. Snodgrass, W. Z. Potter, D. J. Timbrell, and J. R. Mitchell, “Possible mechanisms of isoniazid-related hepatic injury,” Clinical Research, vol. 22, article 323A, 1975. View at Google Scholar
  5. B. K. Park, N. R. Kitteringham, J. L. Maggs, M. Pirmohamed, and D. P. Williams, “The role of metabolic activation in drug-induced hepatotoxicity,” Annual Review of Pharmacology and Toxicology, vol. 45, pp. 177–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Wen, Y. Chen, and W. L. Fitch, “Metabolic activation of nevirapine in human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4,” Drug Metabolism and Disposition, vol. 37, no. 7, pp. 1557–1562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. J. L. Walgren, M. D. Mitchell, and D. C. Thompson, “Role of metabolism in drug-induced idiosyncratic hepatotoxicity,” Critical Reviews in Toxicology, vol. 35, no. 4, pp. 325–361, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. Mitchell, D. J. Jollow, W. Z. Potter, D. C. Davis, J. R. Gillette, and B. B. Brodie, “Acetaminophen-induced hepatic necrosis, I: role of drug metabolism,” Journal of Pharmacology and Experimental Therapeutics, vol. 187, no. 1, pp. 185–194, 1973. View at Google Scholar · View at Scopus
  9. L. Yuan and N. Kaplowitz, “Mechanisms of drug-induced liver injury,” Clinics in Liver Disease, vol. 17, no. 4, pp. 507–518, 2013. View at Google Scholar · View at Scopus
  10. D. N. Assis and V. J. Navarro, “Human drug hepatotoxicity: a contemporary clinical perspective,” Expert Opinion on Drug Metabolism and Toxicology, vol. 5, no. 5, pp. 463–473, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. Z.-X. Liu and N. Kaplowitz, “Role of innate immunity in acetaminophen-induced hepatotoxicity,” Expert Opinion on Drug Metabolism and Toxicology, vol. 2, no. 4, pp. 493–503, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. N. Kaplowitz, “Idiosyncratic drug hepatotoxicity,” Nature Reviews Drug Discovery, vol. 4, no. 6, pp. 489–499, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Jaeschke, “Role of inflammation in the mechanism of acetaminophen-induced hepatotoxicity,” Expert Opinion on Drug Metabolism & Toxicology, vol. 1, no. 3, pp. 389–397, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. M.-A. Robin, M. Le Roy, V. Descatoire, and D. Pessayre, “Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis,” Journal of Hepatology, vol. 26, supplement 1, pp. 23–30, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Bourdi, Y. Masubuchi, T. P. Reilly et al., “Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase,” Hepatology, vol. 35, no. 2, pp. 289–298, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. I. G. Metushi, P. Cai, X. Zhu, T. Nakagawa, and J. P. Uetrecht, “A fresh look at the mechanism of isoniazid-induced hepatotoxicity,” Clinical Pharmacology and Therapeutics, vol. 89, no. 6, pp. 911–914, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Metushi, J. Uetrecht, and E. Phillips, “Mechanism of isoniazid-induced hepatotoxicity: then and now,” British Journal of Clinical Pharmacology, vol. 81, no. 6, pp. 1030–1036, 2016. View at Publisher · View at Google Scholar
  18. I. A. Biraro, M. Egesa, S. Kimuda et al., “Effect of isoniazid preventive therapy on immune responses to mycobacterium tuberculosis: an open label randomised, controlled, exploratory study,” BMC Infectious Diseases, vol. 15, no. 1, article 438, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. O. Krenkel, J. C. Mossanen, and F. Tacke, “Immune mechanisms in acetaminophen-induced acute liver failure,” Hepatobiliary Surgery and Nutrition, vol. 3, pp. 331–343, 2014. View at Google Scholar
  20. Z. Bekker, A. Walubo, and J. B. du Plessis, “The role of the immune system in nevirapine-induced subclinical liver injury of a rat model,” ISRN Pharmaceutics, vol. 2012, Article ID 932542, 11 pages, 2012. View at Publisher · View at Google Scholar
  21. A. Walubo, S. Barr, A. M. Abraham, and C. Coetsee, “The role of cytochrome-P450 inhibitors in the prevention of hepatotoxicity after paracetamol overdose in rats,” Human & Experimental Toxicology, vol. 23, no. 1, pp. 49–54, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. L. L. Von Moltke, D. J. Greenblatt, J. S. Harmatz, and R. I. Shader, “Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes,” Pharmacology, vol. 47, no. 4, pp. 268–276, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. L. L. Von Moltke, D. J. Greenblatt, J. Schmider et al., “Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents,” Journal of Clinical Pharmacology, vol. 36, no. 9, pp. 783–791, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Peter, R. Bocker, P. H. Beaune, M. J. Iwasaki, F. P. Guengerich, and C. S. Yang, “Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1,” Chemical Research in Toxicology, vol. 3, no. 6, pp. 566–573, 1990. View at Publisher · View at Google Scholar
  25. M. D. Burke and R. T. Mayer, “Ethoxyresorufin: direct fluorometric assay of microsomal O-dealkylation, which is preferentially inducible by 3-methylcholanthrene,” Drug Metabolism and Disposition, vol. 2, no. 6, pp. 583–588, 1974. View at Google Scholar
  26. J. Yue, R.-X. Peng, J. Yang, R. Kong, and J. Liu, “CYP2E1 mediated isoniazid-induced hepatotoxicity in rats,” Acta Pharmacologica Sinica, vol. 25, no. 5, pp. 699–704, 2004. View at Google Scholar · View at Scopus
  27. C. Bénichou, “Criteria of drug induced liver disorders. Report of an international consensus meeting,” Journal of Hepatology, vol. 11, pp. 272–276, 1990. View at Google Scholar
  28. G. P. Aithal, L. Ramsay, A. K. Daly et al., “Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity,” Hepatology, vol. 39, no. 5, pp. 1430–1440, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. L. A. Bober, T. A. Waters, C. C. Pugliese-Sivo, L. M. Sullivan, S. K. Narula, and M. J. Grace, “IL-4 induces neutrophilic maturation of HL-60 cells and activation of human peripheral blood neutrophils,” Clinical and Experimental Immunology, vol. 99, no. 1, pp. 129–136, 1995. View at Google Scholar · View at Scopus
  30. K. Kumagai, K. Ito, Y. Ando et al., “Neutralization of IL-10 exacerbates cycloheximide-induced hepatocellular apoptosis and necrosis,” Toxicologic Pathology, vol. 37, no. 4, pp. 536–546, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. T. R. Malek and I. Castro, “Interleukin-2 receptor signaling: at the interface between tolerance and immunity,” Immunity, vol. 33, no. 2, pp. 153–165, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Liao, J.-X. Lin, and W. J. Leonard, “IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation,” Current Opinion in Immunology, vol. 23, no. 5, pp. 598–604, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. T. H. S. Ng, G. J. Britton, E. V. Hill, J. Verhagen, B. R. Burton, and D. C. Wraith, “Regulation of adaptive immunity; the role of interleukin-10,” Frontiers in Immunology, vol. 4, article 129, 2013. View at Publisher · View at Google Scholar
  34. A. Walubo, S. Barr, and A. M. Abraham, “Rat CYP3A and CYP2B1/2 were not associated with nevirapine-induced hepatotoxicity,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 28, no. 7, pp. 423–431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. T. C. Sarich, S. P. Adams, G. Petricca, and J. M. Wright, “Inhibition of isoniazid-induced hepatotoxicity in rabbits by pretreatment with an amidase inhibitor,” Journal of Pharmacology and Experimental Therapeutics, vol. 289, no. 2, pp. 695–702, 1999. View at Google Scholar · View at Scopus
  36. J. R. Mitchell, S. D. Nelson, W. R. Snodgrass, and J. A. Timbrell, “Metabolic activation of hydrazines to highly reactive hepatotoxic intermediates,” in Biological Reactive Intermediates, D. Jollow, J. Kocsis, and R. Snyder, Eds., pp. 271–277, Plenum Press, New York, NY, USA, 1977. View at Google Scholar
  37. S. Sell, Immunology, Immunopathology, and Immunity, Elsevier, New York, NY, USA, 1987.
  38. S. Bolesta and S. L. Haber, “Hepatotoxicity associated with chronic acetaminophen administration in patients without risk factors,” Annals of Pharmacotherapy, vol. 36, no. 2, pp. 331–333, 2002. View at Publisher · View at Google Scholar · View at Scopus